Skip to main content

Table 5 Incidence of vomiting and prolonged QT interval by body weight in the integrated safety analysis and CANTAM

From: Safety and efficacy of pyronaridine–artesunate paediatric granules in the treatment of uncomplicated malaria in children: insights from randomized clinical trials and a real-world study

Adverse event by body weight

Integrated safety analysis

CANTAMb

PA (N = 2599)

PA (N = 667)

AL (N = 358)

Relative risk

% (95% CI)

P valuea

n/N

% (95% CI)

n/N

% (95% CI)

n/N

% (95% CI)

Vomiting

 ≥ 5 to < 8 kg

2/7

28.6 (5.1, 64.1)

1/3

33.3 (1.7, 88.2)

0.86 (0.16, 5.7)

1.00

4/70

5.7 (2.2, 13.8)

 ≥ 8 to < 15 kg

40/319

12.5 (9.3, 16.6)

7/165

4.2 (2.1, 8.5)

3.0 (1.4, 6.4)

0.003

100/1268

7.9 (6.5, 9.5)

 ≥ 15 to < 20 kg

10/341

2.9 (1.6, 5.3)

4/190

2.1 (0.8, 5.3)

1.4 (0.47, 4.2)

0.78

37/1261

2.9 (2.1, 4.0)

Prolonged QT interval

 ≥ 5 to < 8 kg

0/7

0 (0, 35.4)

1/3

33.3 (1.7, 88.2)

0 (0, 1.5)

0.30

0/70

0 (0, 5.2)

 ≥ 8 to < 15 kg

13/319

4.1 (2.4, 6.8)

18/165

10.9 (7.0, 16.6)

0.37 (0.19, 0.73)

0.006

0/1268

0 (0, 0.30)

 ≥ 15 to < 20 kg

8/341

2.3 (1.2, 4.6)

10/190

5.3 (2.9, 9.4)

0.45 (0.18, 1.1)

0.084

0/1261

0 (0, 0.30)

  1. aPyronaridine–artesunate (PA) versus artemether–lumefantrine (AL)
  2. bNote that electrocardiographs were only to be performed if clinically indicated in the CANTAM study whereas they were part of the clinical protocol for the studies included in the integrated safety analysis